Skip to main content
. 2015 Jan 15;7:2. doi: 10.1186/1758-5996-7-2

Table 2.

Baseline demographic and clinical characteristics of the study population*

Group A (Control) Group B (Intervention) P value**
Subjects (n) 12 10
Age (years) 55.4 ± 12.6 60.0 ± 11.3 0.385
Sex (male: female)*** 3:9 4:6 0.652
Duration of Diabetes (years) 16.4 ± 7.9 17.6 ± 9.0 0.745
Body weight (Kg) 78.1 ± 17.4 71.8 ± 20.7 0.444
BMI (Kg/m2) 30.2 ± 6.0 28.4 ± 6.4 0.552
A1C (%) 9.6 ± 1.6 9.0 ± 0.8 0.309
eGFR (ml/min) 75.2 ± 29.0 55.5 ± 30.5 0.137
Insulin treatment duration (years) 11.2 ± 7.4 8.4 ± 6.0 0.344
Entry insulin dose (IU/day) 66.1 ± 19.0 71.7 ± 47.2 0.709
Entry insulin dose (IU/Kg/day) 0.9 ± 0.3 1.0 ± 0.4 0.641
Basal insulin dose (IU/day) 54.3 ± 13.3 56.8 ± 32.3 0.811
Bolus insulin dose (IU/day) 11.8 ± 12.5 14.9 ± 18.5 0.640

BMI, body mass index; A1C, glycated hemoglobin A1C; eGFR, estimated Glomerular Filtration Rate.

*Results are presented as mean ± s.d. (except for Sex, male: female ratio).

**P-values of Independent Student’s t-test, level of significance of 0.05.

***P-values of Exact Fisher’s Test, level of significance of 0.05.